Skip to main content

Table 1 Patient characteristics (n = 46)

From: A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)

Variables

 

n (%) or median (range)

Male: Female

 

28 (61%)/18 (39%)

Age, years

 

68.5 (39-84)

ECOG-PS

0

39 (85%)

 

1

7 (15%)

Primary disease

Extrahepatic

19 (41%)

 

Intrahepatic

8 (17%)

 

Gallbladder

10 (22%)

 

Ampulla of Vater

9 (20%)

Pathologically stage (UICC)

I

10 (22%)

 

II

29 (63%)

 

III

7 (15%)

Surgical procedure

Pancreatoduodenectomy

25 (54%)

 

Hepatectomy (without bile duct resection)

6 (13%)

 

Hepatectomy (with bile duct resection)

6 (13%)

 

Extended cholecystectomy

9 (20%)

Morbidity (Clavien-Dindo ≥3)

Total

10 (22%)

 

Pancreatic fistula

8 (17%)

 

Liver abcess

1 (2%)

 

Intraabdominal abcess

1 (2%)

Residual tumor

0

43 (94%)

 

1

3 (7%)

Lymph node metastasis

Positive

20 (46%)

CEA, ng/dL

 

1.8 (0.1-54.0)

CA19–9, ng/dL

 

17.0 (1.0-3197)

  1. Abbreviations: ECOG-PS Eastern Cooperative Oncology Group Performance Status, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9